Real-world studies results offer insights for treating EGFR-positive NSCLC

  • Real-world data can be useful in determining effectiveness in subgroups not included in randomised clinical trials (RCT)
  • RCTs typically focus on a narrow patient population due to rigid exclusion criteria, real-world studies encompass a broader range of patients therefore real-world data can be useful in determining effectiveness in other subgroups
  • “[For] common mutations and patients with poor performance status, real-world evidence has helped me in making decisions for those specific groups not included in the randomized clinical trials

Federico Albrecht, MD

Click here to learn more.

About SVMPharma

SVMPharma is an innovative strategic consultancy, specialising in Real-World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real-World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.

For more information, please visit and contact us at

ref: NOV2021BS001